



IBA receives marketing authorization for Proteus[®]ONE in Brazil

Louvain-la-Neuve, Belgium, September 18th, 2018, IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has received marketing authorization from the Brazilian Health Regulatory Agency (ANVISA) for its single-room proton therapy solution Proteus[®]ONE*.

Proteus[®]ONE, IBA's single-room proton therapy system is smaller, less expensive, faster to install and includes the latest advances in targeted proton therapy technologies, including IBA's truly compact Image Guided Intensity Modulated Proton Therapy (IG-IMPT). The Proteus[®]ONE has a unique open gantry environment that is easy for radiation therapists to work in and optimizes the patient experience by providing a comfortable environment.

IBA created Proteus[®]ONE to allow more patients access to proton therapy globally and has already sold 24 Proteus[®]ONE systems worldwide. The powerful combination of smaller system size, clinical capabilities and patient-centered design is the reason why Proteus[®]ONE is being adopted by so many advanced institutions around the world.

Olivier Legrain, Chief Executive Officer of IBA commented: "We are delighted to have received marketing authorization from ANVISA which we expect to increase interest in our Proteus[®]ONE* in the region. This is also an exciting milestone for our potential customers in Brazil, where the cost of healthcare is a major focus. Much smaller and more affordable than conventional multi-room proton therapy systems, but with the same clinical applications, Proteus[®]ONE makes proton therapy more accessible both to clinical institutions worldwide and to their cancer patients. With more than 30 years of experience, IBA has designed and installed the majority of clinically operating proton therapy centers in the world and this most recent approval from ANVISA reaffirms our world leading position in the delivery of highly targeted, safer cancer treatment solutions."

Ends

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.



IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

**Proteus®ONE is the brand name of a configuration of the Proteus®235.*

For further information, please contact:

IBA

Daniel Ernult

Proton Therapy Marketing Associate

Tel +32 10 201 287

communication@iba-group.com